Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr01A)
Cicalini S, Antunes F, Balslev U, Bernasconi E, Boaventura JL, Campins M, Evans B, Francioli P, Genasi F, Larsen C, Lot F, Lunding S, Marcus U, Pereira A, Schonwald S, Thomas T, De Carli G, Ippolito G, Puro V;;; INMI Spallanzani, Rome, Italy
BACKGROUND: Occupational post-exposure prophylaxis (OPEP) against HIV represents the standard of care in exposed healthcare workers (HCW), but no general consensus exists on some issues. METHODS: On September 2001, the European Commission funded a project co-ordinated by Italy (I), to evaluate and standardize the manag
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr01B)
Puro V, Cicalini S, Schonwald S, Balslev U, Lot F, Marcus U, Boaventura JL, Campins M, Bernasconi E, Thomas T, De Carli G, Ippolito G; INMI Spallanzani, Rome, Italy
BACKGROUND: Management of occupational HIV post-exposure prophylaxis (PEP) varies among European countries, and several issues remain controversial. METHODS: In September 2001, the European Commission funded a project to standardise the management of occupational HIV PEP in Europe. During a 2-day consensus meeting, exp
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr02)
Gray R, Wawer M, Serwadda D, Sewankambo N, Li X, Mangen FW, Lutalo T, Quinn T, Gange SJ;;; Johns Hopkins University, Baltimore, United States
BACKGROUND: ART or HIV vaccines could reduce potentially control the epidemic. We modeled effects on transmission using data from Rakai, Uganda . METHODS: A stochastic simulation model estimated HIV incidence, probabilities of transmission/ coital act and the reproductive number (Ro) with ART and HIV vaccines. Projecti
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr03)
Nunez CA, Soto RJ, Foreit KG, Ghee AE, Astete S, Lucas D, Bonilla G, Alvarenga MA, Roman M, Guerrero G, Aguilar S, Palma L, Padilla I, Aviles F, Grajales B, Holmes KK;;; PASCA/The Futures Group International (TFGI), Guatemala, Guatemala
BACKGROUND: To determine prevalence of HIV and syphilis among men having sex with men (MSM) and female sex workers (FSW). METHODS: Between May 2001-April 2002, MSM in capital cities of El Salvador , Guatemala , Honduras , Nicaragua
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr04)
Kudrati M, Plummer M, Dafaalla El Hag Yousif N, Mohamed Adam Adham A, Mohamed Osman Khalifa W, Khogali Eltayeb AH, Mohamed Jubara J, Omujwok Apieker V, Ali Yousif S, Mohamed Elnour S;;; Save the Children (USA), Save the Children (UK), Radda Barnen (Sweden), Oxfam (UK), and UNICEF, Sudan, Mwanza, Tanzania
BACKGROUND: Little is understood about the lives of street children in Khartoum, Sudan , particularly as relates to sexual health and risk behaviour. METHODS: 13 adult researchers and 11 child researchers interviewed more than 500 street children in qualitative interviews, and 2,200 street children in a quantitative su
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr05)
Jagwer G, Murethi G, Mwanyika E, Nekesa F, Marum E;;; International Rescue Committee, Kakuma, Kenya
ISSUES: Despite their vulnerability to HIV infection, refugee populations in Africa generally do not have access to specific HIV prevention services such as voluntary counseling and testing (VCT). There are concerns that refugees may refuse VCT due to fear of discrimination. DESCRIPTION: The International Rescue Commit
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr06)
Squire C, Daniel L;;; University of East London, London, United Kingdom
ISSUES: About 1 in 9 South Africans live with HIV. With relatively highly developed infrastructure, health and social services, the country is an important model for African HIV strategies. After initial silence and stigma, awareness and service development are increasing and will expand following recent government dec
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr07)
Chikunjiko G, Orobaton N, Mukuka-Chilaika, Mutonyi S, Mukwakwa C, Mlewa A, Daka D;;; Thandizani NGO, Lundazi, Zambia
ISSUE: In October 2001, Lundazi District Government in Eastern Zambia requested Thandizani NGO to take its highly successful community-based HIV/AIDS prevention and care program to scale. The district government cited that it was no longer equitable for the program to remain in one area of the district given that 10% o
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr08)
Thomas J;;; Advisor, Ministry of Health, Dili, East Timor
This paper summarises the lessons learned from a 12 month HIV/AIDS Prevention activitiy carried out in the newly independent country, East Timor. Indonesia annexed this territory in 1975 after Portuguese colonial rule collapsed. About 200,000 East Timorese were killed or died from disease and famine during a 24-year fi
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr09)
Lange C, Valdez H, Medvik K, Asaad R, Wild M, Kalayjian R, Lederman M;;; Center for AIDS Research, Case Western Reserve University/University Hospitals, Cleveland, United States
BACKGROUND: To ascertain whether delaying antiretroviral therapy will compromise functional immunologic recovery in HIV-1 infection we studied patients who normalized circulating CD4+ T-cell counts after HAART using responses to immunization as a measure of functional immunologic competence. METHODS: Twenty-nine HIV-1
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr10)
Amado R, Mitsuyasu R, Rosenblatt J, Ngok F, Bakker A, Cole S, Chorn N, Lin LS, Bristol G, Miles S, Boyd M, MacPherson J, Fanning G, Todd A, Ely J, Zack J, Symonds G;;; University of California, Los Angeles
BACKGROUND: The cellular introduction of genetic elements that inhibits HIV is conceptually attractive as a new treatment paradigm for AIDS. By ex vivo retroviral transduction, we have introduced a HIV-1 (tat gene) targeted ribozyme (RRz2) and a control construct (LNL6) into G-CSF mobilized CD34+ hematopoietic progenit
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr11)
Lisziewicz J, Xu J, Lewis M, Trocio J, Whitman L, Lori F;;; Research Institute for Genetic and Human Therapy, Washington, DC, United States
BACKGROUND: Several studies have demonstrated that vigorous HIV-specific T cell immune responses can suppress virus replication and eliminate HIV-infected cells. These findings provided the rationale for the development of therapeutic vaccines. METHODS: We showed that a novel topical DNA vaccine (DermaVirtm) could tran
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr12)
Tilton J, Iyasere C, Migueles S, Laborico A, Connors M;;; Laboratory of Immunoregulation/NIAID/NIH, Bethesda, MD, United States
BACKGROUND: Proliferative responses to HIV antigens are absent in most untreated patients despite persistence of significant frequencies of HIV-specific CD4+ T cells. Strong HIV-specific CD4+ T cell responses to viral antigens are thought to contribute to restriction of virus replication. The HIV-specific CD4+ T cell r
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr13)
Gray G, Urban M, Violari A, Chersich M, van Niekerk R, McIntyre J;;; Perinatal HIV Research Unit, Soweto, South Africa
BACKGROUND: To date, Nevirapine prophylaxis to mother and infant provides the most feasible option for the prevention of Mother to child transmission (MTCT) of HIV-1 in developing countries. What is not known is the value of post-exposure prophylactic (PEP) antiretroviral therapy in reducing MTCT where women did not ac
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr14)
de Souza M, Karnasuta C, Cox J, Nitayaphan S, Pittisituttithum P, Brown A, Gurunathan S, Heyward W, McNeil J, Birx D;;; AFRIMS, Bangkok, Thailand
BACKGROUND: The frequency of cytotoxic T lymphocyte (CTL) responses was determined in HIV-seronegative recipients of canarypox (ALVAC-vCP1521) expressing HIV subtype E Env and B Gag/Pro and HIV recombinant bivalent gp120 (AIDSVAX® B/E) as a boost. METHODS: The injection regimen was 0, 1, 3 and 6 months. Five subject
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr15)
Stern J, Lanes S, Love J, Robinson P, Imperiale M, Mayers D;;; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, United States
BACKGROUND: The relationship between drug-induced elevations in ALT/AST levels and subsequent significant clinical liver injury is variable and often unpredictable. All ARV classes have been associated with asymptomatic ALT/AST elevations as well as severe, and at times life threatening, clinical liver toxicity. METHOD
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr16)
Perronne C, Carrat F, Bani Sadr F, Hor T, Morand P, Lunel F, Rosenthal E, Pol S, Cacoub P; ANRS, Paris, France
BACKGROUND. HCV morbidity and mortality is increasing in HIV-infected patients. We compared the safety, tolerability, and efficacy of a 48 week-course of the standard (IFNa2b: 3 MIU x3/w, n=210) to the pegylated (PEG-IFNa2b: 1.5 µg/kg x1/w, n=206) interferon + ribavirin combination (800mg/d, = 12 mg/kg/d). METHODS.
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr17)
Staszewski S, Gallant J, Pozniak A, Suleiman JM, DeJesus E, Koenig E, Coleman S, Lu B, Cheng AK, Coakley DF; University Hospital, J.W.Goethe-Universitat, Frankfurt, Germany
BACKGROUND: TDF is a single tablet, once daily nucleotide analog reverse transcriptase inhibitor with potent activity against wild-type and nucleoside resistant HIV. Prior studies have demonstrated significant anti-HIV activity when TDF was added to stable background ART in treatment-experienced patients. Study 903 was
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr18)
Kotler DP, Thompson M, Grunfeld C, Testa M, Turner R, Gertner J, Muurahainen N; Columbia University, New York, United States
BACKGROUND: This placebo-controlled, multi-center trial evaluated recombinant human growth hormone (r-hGH, Serostim®) in HIV-associated adipose redistribution syndrome (HARS). HARS patients (pts) have pathological accumulation of visceral adipose tissue (VAT), often with metabolic abnormalities. METHODS: To be eligb
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr19A)
Clotet B, Lazzarin A, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Chung J, Fang L, Delehanty J, Salgo M;;; irsiCaixa Foundation
BACKGROUND: Enfuvirtide (T-20; ENF) is the most advanced agent in a new class of investigational ARV, the Fusion Inhibitors, that blocks gp41-mediated fusion of HIV-1 to host cells. TORO 2 (T-20 vs Optimized Regimen Only) is the second Phase III study of enfuvirtide, similar in design to TORO 1. METHODS: Patients from
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr19B)
Henry K, Lalezari J, O'Hearn M, Trottier B, Montaner J, Piliero P, Walmsley S, Chung J, Fang L, Delehanty J, Salgo M;;; Hennepin County Medical Center, Minneapolis, United States
BACKGROUND: Enfuvirtide (T-20; ENF) is an HIV fusion inhibitor, a new class of investigational ARV that blocks gp41-mediated fusion of HIV-1 to the host cell. TORO 1 (T-20 vs Optimized Regimen Only) is one of two Phase III studies of enfuvirtide, and is similar in design to TORO 2 performed in Europe and
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr20A)
Robbins G, Shafer R, Smeaton L, De Gruttola V, Pettinelli C, Snyder S, D'Aquila R, Vella S, Merigan T, Hirsch M; MGH/Harvard Univ., Boston, MA, United States
Intro: 6-arm study of 980 naive Pts. 2x3 factorial design: A. ZDV+ 3TC vs d4T + ddI , B. EFV vs NFV, C. 3 vs 4 drugs. This abstract compares sequential 3-drug regimens (obj.
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr20B)
Shafer R, Robbins G, Smeaton L, De Gruttola V, Pettinelli C, Snyder S, D'Aquila R, Vella S, Hirsch M, Merigan T; Stanford University, Stanford, CA, United States
Intro: 6-arm study of 980 naive Pts. 2x3 factorial design: A. ZDV+ 3TC vs d4T + ddI , B. EFV vs NFV, C. 3 vs 4 drugs. This abstract compares sequential 3-drug regimens vs single 4-drug regi
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr21)
Palefsky J, Holly E, Ralston M, Jay N, Berry M, Darragh T;;; UCSF, San Francisco, United States
BACKGROUND: HAART has led to declines in the incidence of Kaposi s sarcoma and non-Hodgkins lymphoma but its effect on HPV-associated anogenital cancers is unclear. The incidence of anal cancer is 37-fold higher among HIV+ MSM compared with the general population of men. Anal cancer most likely is preceded by anal intr
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr22)
Lallemant M, Jourdain G, Le Coeur S, Mary JY, Koetsawang S, McIntosh K, Ngo-Giang-Huong N, Kanshana S, Thaineua V;;; UR54 - Institut de Recherche pour le Developpement, Chiang Mai, Thailand
BACKGROUND: ZDV starting at 28 weeks? gestation decreases ?in utero? transmission to 1-2%, but 4-5% ?intrapartum? transmission still occurs. Adding NVP to ZDV during labor and in neonates may further reduce intrapartum transmission. METHODS: Eligibility: ZDV prophylaxis from 28 wks?gestation or as soon as possible ther
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr23)
Gabbay M, Thomas J, Gibbs A;;; University of Liverpool, Liverpool, United Kingdom
BACKGROUND: Condom failures potentially expose couples to 255M pregnancies & STIs each year worldwide, acting as a disincentive to their use. Our large RCT investigated the impact of additional spermicide on condom failure. METHOD: Adult heterosexual condom users in stable relationships were randomized using a cros
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbOr24)
Rerks-Ngarm S, Pitisuttithum P, Kitayaporn D, Nitayaphan S, Gurunathan S, Heyward W, Brown A, McNeil J;;; Ministry of Public Health, Bangkok, Thailand
Purpose: To describe the plan for initiating and implementing a community-based, phase III efficacy trial of a prophylactic HIV candidate vaccine combination in Thailand . METHODOLOGY: Trial objectives: Determine whether this vaccine combination 1) reduces the HIV infection rate by at least 50%, and/or 2) results in de
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeA9001)
Petitprez K, Kahi S, Jacques S, Andrieu M, Pretet JL, Hosmalin A, Butor C;;; ANRS, Paris, France
BACKGROUND: Dendritic cells (DC) are absolutely required to activate naive T cells and they induce crucial early innate immune responses. Two major populations are found in the blood: myeloid CD11c+ DC, which secrete IL-12, and plasmacytoid CD123 (IL-3-R)+ DC, which secrete type I interferons, strong antiviral cytokine
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeA9002)
Velazquez-Campoy A, Vega S, Freire E;;; The Johns Hopkins University, Baltimore, United States
The vast majority of HIV-1 infections worldwide are caused by the C and A viral subtypes rather than the B subtype prevalent in the United States and Western Europe. Genomic differences between subtypes give rise to sequence variations in the encoded proteins, including those identified as targets for antiretroviral th
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeA9003)
Darbha R, Phogat S, Labrijn A, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Burton D, Dimitrov D, Ji X;;; NCI-Frederick, NIH, Frederick, United States
BACKGROUND: HIV entry into host cells is initiated by formation of a complex between the viral envelope glycoprotein gp120, the primary receptor CD4 and a coreceptor (typically CCR5 or CXCR4). Recently, a novel broadly neutralizing human monoclonal antibody Fab to HIV-1, X5, was isolated from a phage display library us
BACKGROUND: To date, no clinical study has shown virological efficacy of an HIV-1 therapeutic vaccine. METHODS: Multicenter, double-blind clinical trial in asymptomatic, HIV-infected adults, with no prior antiretroviral therapy and with CD4 counts between 300 and 700/mm3. Subjects were randomised to receive an immunoge
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeA9005)
Winchester R, Pitt J, Magder L, Charurat M, Ott J, Landay A, Read JS, Shearer W, Handelsman E, Luzuriaga K, Hillyer G, Blattner W;;; Columbia University, New York, United States
BACKGROUND: While certain HLA-B alleles are associated with the rate of HIV disease progression, their role in transmission is not known. METHODS: To determine the association of HLA-B alleles with maternal-infant transmission of HIV-1, 83 transmitting and 163 non-transmitting mother infant pairs in the WITS cohort wer
BACKGROUND: CD8+ lymphocyte response is fundamental in protection against HIV infection, in association with CD4+ lymphocyte and antibody responses. Dendritic cells (DC) are required for the activation of naive T lymphocytes, and thus they have a central role in the induction of protective immune responses during HIV i
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeA9007)
Young S; Merck &Co., Inc, West Point, PA, United States
Current therapies available for treatment of HIV infection target only two of the three constitutive viral enzymes required for replication, namely the reverse transcriptase and protease. The third enzyme, HIV-1 integrase, is an attractive target for chemotherapeutic intervention in the treatment of AIDS in large part
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeA9009)
Inwoley A, Recordon P, Minga A, Gaston J, Dupuis M, Fleury H, Rouet F, Guillet JG, Andrieu M; CeDRes/PAC-CI, Abidjan, Cote d'Ivoire
BACKGROUND: The great variability of protein sequences from HIV-1 may represent a major obstacle to the development of an effective vaccine against the virus. In this study we evaluate the impact of variability among different HIV-1 clades on CD8 T recognition. We analysed whether CD8 T cells from Ivorian patients infe
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9010)
Strayer D, Blick G, Mitchell W, Cimoch P, Carter W;;; Hemispherx Biopharma, Inc., Philadelphia, United States
BACKGROUND: Prolonged use of highly active antiretroviral therapy (HAART) has been associated with long term, potentially fatal, toxicities. Structured treatment interruption (STI) of HAART in chronically HIV-infected individuals to augment protective Th1 immune responses in order to achieve prolonged control of HIV-1
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9011)
Mitchell W, Blick G, Strayer D, Cimoch P, Carter W;;; Vanderbilt University, Nashville, United States
BACKGROUND: Poly I:poly C12U, a specifically mismatched dsRNA, is a biological response modifier with anti-HIV activity that is synergistic with a majority of FDA approved ARV agents. Poly I:poly C12U has a novel mechanism of activating the intracellular antiviral mediators, 2-5A synthetase/RNase L. METHOD: Poly I:poly
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9012)
Daar E, Gertner J, Kotler D, Melchior JC, Moyle G, O'Brien F, Svanberg E;;; Cedars-Sinai Health Sciences, Los Angeles, United States
Wasting with lean body mass (LBM) loss is a major complication in AIDS for which r-hGH (Serostim®) was approved before the introduction of HAART. Since then prevalence has fallen, but it remains a chronic debilitating, life threatening condition. The aim of this study was to evaluate the effect of r-hGH for the trea
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9013)
Murphy R, Thiry A, Mancini M, Pokrovsky V, Rozenbaum W;;; Northwestern University, Chicago, IL, United States
BACKGROUND: Atazanavir (ATV) is a potent, safe, and effective QD PI in Phase III development. In AI424-008, ATV was associated with a lipid profile superior to nelfinavir (NFV). AI424-008 completers were treated with ATV/
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9014)
Baril JG, Pollard RB, Raffi F, Whelden M, Rutkiewicz V, Brett-Smith H;;; Clinique du Quartier Latin, Montreal, Canada
BACKGROUND: A multinational, randomized, double-blind, placebo-controlled study evaluated the antiviral activity, safety and tolerability of once-daily d4T extended/prolonged release capsules (XR/PRC) compared to the current twice-daily formulation of d4T immediate release (IR), when used in a HAART regimen in treatmen
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9015)
Nunez M, Perez-Olmeda M, Diaz B, Rios P, Garcia-Samaniego J, Gonzalez-Lahoz J, Soriano V;;; H. Carlos III, Madrid, Spain
BACKGROUND. Treatment of hepatitis B virus (HBV) infection with lamivudine ( 3TC ) may not completely suppress viral replication and often fails over time due to the development of 3TC resistance
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9016)
Papasavvas E, Grant R, Jun-wei Sun, Mackiewicz A, Pistilli M, Kostman J, Mounzer K, Montaner LJ;;; Wistar Institute, Philadelphia, United States
BACKGROUND: The effect of TIs on the evolution and persistence of drug-resistant viruses in chronically HIV-1 infected suppressed patients is undetermined. METHODS: The emergence of viral resistance to ART was monitored in 11 suppressed chronically HIV-1 infected patients (mean follow-up=326 days) undergoing from 1 up
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9017)
Negredo E, Ribera E, Viciana P, Pedrol E, Miralles C, Galindo MJ, Puig J, Gel S, Arisa ER, Fumaz CR, Sirera G, Gomez G, Videla S, Clotet B;;; Lluita contra la SIDA Foundation. Germans Trias i Pujol Hospital, Barcelona, Spain
BACKGROUND: Antiretroviral therapy is not able to eradicate HIV infection. Simplified strategies are required in order to assure prolonged adherence. OBJECTIVE: To demonstrate the safety and the efficacy of once-daily (QD) administered NVP+DDI+TDF in antiretroviral-experienced patients (pt), as well as to study the pha
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9018)
Aberg J, Zackin R, Evans S, Yang Y, Alston B, Henry K, Glesby M, Brobst S, Owens S, Fichtenbaum C;;; Washington University, Saint Louis, United States
OBJECTIVE: To determine whether fenofibrate (F) and pravastain (P) are equivalent and the safety of these agents in the treatment of HIV-related dyslipidemia at week 12 METHODS: HIV- infected persons with dyslipidemia (LDL >/= 130 mg/dL and TG >/= 200 mg/dL) on ART for > 6 months were randomized to receive either P 40
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9019)
Maggi P, Fiorentino G, Epifani G, Perilli F, Lillo A, Ladisa N, Ferraro S, Gargiulo M, Chirianni A, Regina G, Pastore G;;; Institute of Infectious Diseases - University of Bari, Bari, Italy
BACKGROUND: Several reports have indicated that HIV-positive patients seem to have an increased risk of cardiovascular diseases, although the role of treatment with PI remains a controversial issue. Color doppler ultrasonographic study of the epiaortic vessels is a safe and sensitive technique capable to detect initial
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9020)
Ruane P, Richmond G, DeJesus E, Hill-Zabala C, Danehower S, Liao Q, Johnson J, Shaefer M;;; Tower ID Medical Associates, Los Angeles, United States
BACKGROUND: Recent intracellular zidovudine (ZDV) triphosphate data suggest that ZDV may be dosed once daily (QD). This 14-day pharmacodynamic study compared the virologic activity of ZDV monotherapy administered as 600mg QD v. 300mg BID. METHODS: Antiretroviral-naive subjects (>/=18 years, HIV RNA >/=7,500 c/mL, CD4 >
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9021)
Negredo E, Bonjoch A, Sirera G, Puig J, Videla S, Kurowski M, Bonafont X, Ruiz L, Clotet B;;; Lluita contra la SIDA Foundation. Germans Trias i Pujol Hospital, Barcelona, Spain
BACKGROUND: NRTIs have been recently linked to mitochondrial toxicity (MT). Nevirapine (NVP) has been associated with a favourable lipid profile while lopinavir/ ritonavir (LPV/rtv) increases cholesterol and triglyceride levels.
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9022)
Mallolas J, Laguno M, Murillas J, Sanchez-Tapias JM, Bianchi L, Miquel R, Garcia-Gasalla M, Blanco JL, Martinez E, Milinkovic A, Leon A, Lonca M, Gatell JM;;; Hospital Clinic, Barcelona, Spain
BACKGROUND: Although HCV is a major morbidity in HIV infected patients, current therapies has low success and high intolerance. We evaluate the efficacy and safety of interferon (IFN) + ribavirin (RBV) vs PEG-INF + RBV in co-infected patients. METHODS: This is a randomized, single center, open label trial. Inclusion cr
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9023)
Raguin G, Taburet AM, Chene G, Morand-Joubert L, Droz C, Vincent I, Clavel F, Girard PM;;; Hopital Saint-Antoine, Paris, France
BACKGROUND: A combination of APV, LPV and RTV could prove effective in pts failing multiple antiretrovirals (ARV) provided that pk interactions between APV and LPV have no negative effect on virologic response. METHODS: A prospective, randomized, open-label, multicentre trial in pts with CD4+ 10.000 copies/ml
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9024)
Sullivan J;;; University of Massachusetts Medical School, Worcester, United States
BACKGROUND: Selection of resistance mutations was determined in a trial of two doses of nevirapine (NVP) compared with 7 days of zidovudine / lamivudine (ZDV/
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9025)
Lori F, Maserati R, Foli A, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Tinelli C, D'Aquila R, Lisziewicz J;;; RIGHT at Policlinico S. Matteo, Pavia and Washington DC, Pavia, Italy
BACKGROUND: Pilot, uncontrolled studies in chronically infected patients suggested that STI cause the loss of CD4 T cells and the onset of drug resistance. Maintaining CD4 counts and resistance profiles similar to those seen during continuous HAART would represent a significant improvement of STI. METHODS: RIGHT 901 ra
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9026)
Kearney BP, Damle B, Plummer A, Sayre J, Zhang X, Ryan K, Cheng AK;;; Gilead Sciences, Foster City, CA, United States
BACKGROUND: A previous PK study identified increases in ddI Cmax and AUC (28% and 44%) when TDF and ddI (buffered tablets) were co-administered. The primary objective of this study was to evaluate whether ddI or tenofovir PK were affected by co-administrat
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9027)
Lopez S, Miro O, Martinez E, Rodriguez B, Milinkovic A, Predrol E, Casademont J, Nunes V, Gatell JM, Cardellach F;;; Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Catalunya, Spain
BACKGROUND: Mitochondrial (mt) toxicity is supposed to be the deleterious effect of nucleoside reverse transcriptase inhibitors. We comprehensively assessed mt content and function in easy-to-obtain samples such as peripheral lymphocytes. METHODS: Five groups of HIV-infected patients without clinically evident body fat
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9027B)
Katlama C, Tubiana R, Ghosn J, Wirden M, Shoen H, Harmenberg J, Mardh G, Westling C, Calvez V;;; Hopital Pitie-Salpetriere - Service Maladies Infectieuses, Paris, France
BACKGROUND: MIV-310 (3 -deoxy-3 -fluorothymidine) is a nucleoside analogue RT inhibitor which exhibits potent in vitro efficacy against NRTI resistant viral strains. METHODS: This phase II pilot study had included 15 pts failing a NRTI-containing regimen with HIV RNA > 1000 cp/ml, with at least 2 TAMs on genotypic assa
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeC9028)
Turner AN, De Kock A, Sebola M, Meehan A, Blanchard K, Hoosen A, Coetzee N, Ellertson C;;; Population Council, Mexico City, Mexico
BACKGROUND: Assessing the reliability of self-reports of sensitive behavior, particularly in HIV-prevention microbicide trials, is critically important. If participants report their use of study drugs or devices inaccurately, study conclusions about safety and effectiveness could be wrong. METHODS: We used audio comput
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeC9029)
Loscertales MP, Menendez C, Quinto L, Castellsague X, dos Santos F, Lloveras B, Abarca N, Bosch FX, Alonso PL;;; CISM, Manhica, Mozambique
BACKGROUND: There is little information on the prevalence of sexually transmitted diseases (STD) in rural areas of sub-Saharan Africa, where STDs are one of the major public health problems and their impact in mother and child morbimortality is especially relevant in the context of HIV epidemic. METHODS: An age-stratif
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeC9030)
Calmet M, Barrabeig I, Sanz B, Armengol P, Boronat J, Villena MJ, Vall M, Dominguez A;;; Directorate of Public Health. Department of Health and Social Security, Barcelona, Spain
BACKGROUND: Ulceratives STIs and HIV infection are potent co-factors of its sexual transmission. There has been a recent shift in the epidemiology of early syphilis in the developed world and outbreaks of syphilis have recently been reported in many Member states of European Union. Over the last few years the number of
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeC9031)
Bolding G, Sherr L, Elford J;;; City University, London, United Kingdom
BACKGROUND: As clinical trials enter phase III, will high-risk HIV negative gay men volunteer to take part? METHODS: 506 HIV negative gay men were surveyed at community venues in central London in February 2002. They were asked about the likelihood of their volunteering for an HIV vaccine trial, attitudes to HIV vaccin
Introduction The man objective of this work is to measure and follow up the trends of the HIV/AIDS epidemic and to monitor the progress of the prevalence rates among selected groups. Material and methods The selected groups that have been studied were the STI s patients as high-risk group, the sex workers as very high-
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeC9033)
Wu A, Safaeian M, Shah N, Strathdee S, Vlahov D, Celentano D;;; Johns Hopkins Bloomberg School of Public Health, Baltimore, United States
BACKGROUND: Highly active antiretroviral therapy (HAART) can effectively suppress HIV replication, however it can also reduce quality of life (QOL). There is little data on the impact of HAART on QOL of injection drug users (IDUs). The objective of this study was to compare the QOL of HIV positive IDUs on HAART with HI
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeC9034)
Kububa P, Dube L, Midzi SM, Nesara P, St. Louis ME;;; Ministry of Health, Harare, Zimbabwe
BACKGROUND. Zimbabwe has experienced a severe generalized HIV epidemic, and the aggregate HIV prevalence in HIV surveillance in antenatal care centers (ANC) in 2000 was 35%. METHODS. To monitor progress in response to the epidemic, ANC surveillance was repeated in 2001 in 19 designated HIV sentinel sites. Up to 500 con
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeC9036)
Sifakis F, Hylton J, Solomon L, Flynn C, MacKellar D, Valleroy L, Celentano D;;; The Johns Hopkins Bloomberg School of Public Health, Baltimore, United States
BACKGROUND: To estimate HIV incidence and ascertain racial/ethnic differences in the burden of HIV infections among young men who have sex with men (MSM). METHODS: The Young Men Survey was a cross-sectional, venue-based, sample survey conducted in two phases in Baltimore, Maryland, U.S.A. MSM between the ages of 15 and
BACKGROUND: Surveillance of sexually transmitted infections (STI) is integral to second generation HIV surveillance. This review examines the use of STI data in explaining the HIV epidemic and informing prevention strategies. METHODS: STI database was developed based on annual updates from Western Pacific countries (WP
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeD9038)
Klein D, Hurley L, Merrill D, Quesenberry C, Allerton M;;; Kaiser Permanente, Hayward, United States
BACKGROUND: HIV infection is now a treatable chronic condition. Early detection can improve prognosis and reduce transmission, but 30-40% of cases are diagnosed with advanced immunodeficiency. This study was designed to evaluate whether medical encounters in the five years prior to a diagnosis of HIV infection represen
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeD9039)
Garcia Ruiz M, Vidal Amalia F, del Valle Ricardo D, Alvarez Oscar S, del Valle Jorge F;;; Consejo de la Juventud de Asturias, Oviedo, Spain
BACKGROUND: Describe risk and prevention behaviors regarding to sexual transmision of HIV among teenagers(aged 14-21) living under residential care to propose a prevention programme. METHODS: A cross-sectional descriptive study in 3 autonomous regions with different prevalence levels of HIV. 329 youngsters completed a
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeD9040)
Ravizza M, Foina S, Seveso A, Magiarotti L, Ierardi MG, Serafini P, Pariani S, Ragusa G, Pardi G;;; Department of Obstetric and Gynaecology, San Paolo Hospital, University of Milan, Milan, Italy
BACKGROUND: Sexual transmission remains by far the predominant mode of hiv infection. Since 1990 we have been assisting hiv discordant couples (men hiv positive and women hiv negative) with sperm washing to reduce risk of hiv transmission by intrauterine insemination (aih) and in vitro fertilisation (ivfet). Aim of thi
BACKGROUND: Drug(opium,heroin)used situation among people from the Arkha hiltribe minority group is very high. The strategy of harm reduction by community base care should be the effectiveness strategy to control HIV/AIDS,risk behavior,reduce drugs demand and crime and increse quality of life in drug user group. METHOD
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeD9042)
Mutevedzi T, Routh J, Khumalo-Sakutukwa G, Fritz K, Morin S;;; University of Zimbabwe-University of California San Francisco (UZ-UCSF), Harare, Zimbabwe
BACKGROUND: Voluntary HIV Counseling and Testing(VCT) is an effective method of promoting behavior change and reducing stigma in sub-Saharan Africa. However, utilization of VCT is still low in African communities with a high prevalence of HIV. As part of a demonstration study of mobile VCT(MVCT) in Epworth,
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeD9043)
Ptah A;;; Harm Reduction Coalition, New York, United States
BACKGROUND: African-American communities have been hardest hit by drug-related AIDS, harm reduction remains controversial and practitioners remain isolated. Goal is to develop and implement harm reduction policy and practice within African American community-based organizations and the communities with whom they work,
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeD9044)
Silveira D, Silveira ED;;; PROAD/Dept. of Psychiatry/Federal University of Sao Paulo, Sao Paulo, Brazil
BACKGROUND: Only a small percentage of Brazilian addicts use IV drugs. The main objective of this survey is to describe factors related to AIDS risk behaviour among Brazilian addicts. METHODS: We interviewed 1056 addicts from an outpatient care unit in Sao Paulo, Brazil, to examine possible risk behaviours associated t
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeD9045)
Thinh T, Bain D, Giang L, Mandel J, Lindan C;;; Ho Chi Minh City AIDS Committee, Ho Chi Minh City, Vietnam
BACKGROUND: Vietnam s first and only anonymous HIV test site (ATS), opened in Ho Chi Minh City in November, 2001. Our objective was to attract at-risk individuals who might otherwise not seek testing for fear that their HIV sero- or risk status would be reported and become community knowledge. To date, HIV surveillance
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeE9047)
Sarkar S, Choudhury SK;;; West Bengal State AIDS, Kolkata, India
A cross sectional Survey was carried out in Ghutiary Sharif, South 24 Parganas among Commercial Sex Workers during the period from 1st to 31st August, 2001. Most of the sex workers are below 30 yrs. (55,9%) of age. It is observed that the income of the respondents (N=1000, respondents were chosen by try and trial metho
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeE9048)
Ansell N, Young L;;; Brunel University, Uxbridge, United Kingdom
Background Most southern African orphans are cared for by extended families, but the implications of the spatial dispersal of southern African families are seldom recognised: orphans migrate to new homes and communities. This paper compares orphans migration experiences to assess how successful migration might best be
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeE9049)
Kongsin S, Watts C, Jiamton S;;; Faculty of Public Health, Mahidol University, Bangkok, Thailand
BACKGROUND: The study aims to: identify the patterns and duration of health-care use by chronically ill adults and their care-givers; and explore the implications for health care provision and financing. METHODS: The study was conducted in two districts in Phayao Province, Thailand : one district has active support se
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeE9050)
Robalino D, Jenkins C, El Maroufi K;;; World Bank, Washington, United States
BACKGROUND: In MENA countries, continued low levels of case detection through mostly mandatory screening, the lack of appropriate behavioral data, and over-confidence in the protective effects of social and cultural conservatism have dictated low priority for HIV/AIDS. This paper is a first attempt to evaluate the risk
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeF9051)
Chowdhury AA, Jana S;;; CARE-Bangladesh, Dhaka, Bangladesh
ISSUES: Many STD patients including the members of the high risk and bridging population visit the local pharmacist for the management of their STDs. And most of these pharmacists do not have any training on Syndromic case management. DESCRIPTION: CARE- Bangladesh is implementing HIV prevention program for the high ris
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeF9052)
Alaei K, Alaei A, Mansoori D, Heravi MM, Tabar HN;;; HIV/AIDS counselling &care center, Kermanshah, Islamic Republic of Iran
ISSUES: HIV/AIDS care centers has developed with sharing of peer practices and general population and articulated problems faced by HIV cases and their familes. DESCRIPTION: In this program we have coverd 363 HIV positive patients that by their peer practices we have had 3002 voluntarily counselling in drug users an 59
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeF9053)
Alam S, Manning G, Durrany K, Siddiqui N, Siddiqui G, Akhtar N, Alam M;;; Sharan - Society for service to urban poverty, New Delhi, India
ISSUES: Religious leaders are important members of Muslim communities. They can act as catalysts or barriers in the development of responses to HIV. They do not exert their influence in isolation, but as parts of broader networks of influence. The need for a multi-sectoral response to HIV extends to Muslim communities
ISSUES: To determine the impact of the HIV and AIDS epidemic on its mining operations, Debswana Diamond Company undertook a voluntary and anonymous saliva screening of all employees. Information gained was used to determine the feasibility of providing anti retroviral therapy to HIV infected employees. DESCRIPTION: Bet
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeF9055)
Cloutier M, Vandenberg G;;; Springboard and Homebase Programs, Continuum HIV Day Services, San Francisco, United States
ISSUES: HIV-positive prison- and jail- inmates who have been receiving HAART while incarcerated face a number of challenges upon their release. Access and adherence to anti-retroviral therapy will often take a back seat to finding shelter, nutrition, income, drugs for those who are addicted, and re-establishing family
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeF9056)
Cervantes R, Kappos B, Gonzalez G;;; Clinic, East Los Angeles, United States
ISSUE: According to the 1999 LA County, HIV Strategic Plan, Latinos account for an increasing percentage of AIDS cases. Among AIDS cases diagnosed in 1997, Latinos accounted for the largest percentage of all AIDS cases (39%) for the first time. Census tracts with low median household incomes have the highest cumulative
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeG9057)
Niyongabo C;;; Save the Children, UK, Gitega, Burundi
ISSUES: For a long time, the response to HIV/AIDS in Burundi has been centralised and sector-specific. However the HIV/AIDS problem in Burundi is a result of a combination of socio-cultural factors including taboos surrounding sex and sexuality, high illiteracy rates and other socio-cultural factors which cannot be add
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeG9058)
Namur J;;; Danya International, Inc., Silver Spring, MD, United States
ISSUES: A vast amount of research addresses violence against women and HIV/AIDS in women as individual issues, but little qualitative or quantitative research has been conducted pertaining to the intersection of these two public health issues. Despite the fact that For millions of girls and women worldwide it is clear
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeG9059)
Peel S, Powell G;;; Pendulum Project, Cambridge MA, United States
ISSUES: Current and future increases in numbers of children orphaned by AIDS require policy measures to cost-effectively and meaningfully reach many children. DESCRIPTION: Contrasting programming with policy: models of care, time frame, quality of care, scale and scalability. LESSONS LEARNED: Traditional responses to o
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeG9060)
Masi V, Sommerfeld C;;; Medecins Sans Frontieres, Lagos, Nigeria
BACKGROUND: The HIV sero prevalence in Nigeria at the end of 2001 was estimated at 5.8% --3.1 million persons. Nigeria has the second highest number of HIV-positive persons in the world, behind South Africa . Among the high-risk groups, female sex workers (FSWs) are of special interest because they are highly stigmatis
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2201)
Unge R, Brugha R, Faxelid E, Kabatesi D, Mayuad P, Ndubani P, Ssengooba F, Vongo R;;; Karolinska Institutet, Stockholm, Sweden
In a three year EU funded project, feasibility and potential benefits of collaboration between the traditional and public health care sectors in Uganda and Zambia will be assessed. STI/HIV/AIDS and policy researchers from UK, Sweden , Uganda and Zambia and organisations of traditional healers in Uganda
BACKGROUND: Angola s 27-year civil war may have inadvertently limited HIV transmission by severely restricting mobility within the country. It s HIV prevalence is estimated to be 4% of the general population compared to rates of 20% to 35% in neighboring sub-Saharan African countries. Military personnel, generally youn
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2203)
Scott M;;; American Red Cross/International Federation of Red Cross and Red Crescent Societies, Lilongwe, Malawi
ISSUES: as HIV/AIDS continues its worldwide spread, our response gains momentum. We still need to explore approaches that broaden capacity to transfer already-developed, successful interventions. We must revisit global thinking and explore new avenues of fighting the epidemic to save time and funds. One underutilized s
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2204)
Smith A, Mitchell C;;; University, Johannesburg, South Africa
ISSUES: Youth worldwide are one of the most vulnerable populations for risk of infection of HIV. Young women are particularly at risk. Too often, however, prevention programs tend to be ?about? young people or are ?for? young people but are not developed with young people themselves. Moreover, such programs often ignor
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2205)
Balhara S, Apoya P, Theophillus A;;; Community Partnerships For Health And Development, Tamale, Ghana
ISSUES: With increasing interest among policy makers towards Mutual Health Organizations (MHOs), there has been an exponential growth in the literature analyzing different aspects of MHOs. However, there remains little or no evidence base linking MHOs to HIV/ AIDS control. This paper assesses performance of MHOs in ter
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2206)
Moneti F;;; International Labour Organization, Geneva, Switzerland
ISSUES What community-based mechanisms can enhance the capacity of poor families in the informal economy to access health care and take action to prevent the spread of HIV/AIDS? Evidence is growing that health micro-insurance (HMIS), an innovative decentralized system of social protection, can play an important role. D
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2207)
Pereira C, Paridaen J, Rutten K, Huigen M, Bovenkamp M, Middel J, Jastrzebski J, Schuurman R, Marnett L, Verhoef J, Nottet H;;; University Medical Center Utrecht, Utrecht, The Netherlands
BACKGROUND: Anti-inflammatory molecules are proposed in HIV-1-associated dementia (HAD) therapy. Some anti-inflammatory molecules are also known to possess anti-HIV activity. We found that o-(acetoxyphenyl)hept-2-ynyl sulfide (APHS), a recently synthesized non-steroidal anti-inflammatory molecule can inhibit HIV-1 repl
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2208)
Stek M Jr, Hirschel B, Benetucci J, Reboredo G, Begovac J, Banhegyi D, Stankova M, Duiculescu D, Patel K, Shivaprakash M, Georgiou N, Menten J;;; Merck & Co., Inc., Whitehouse Station, NJ, United States
OBJECTIVES: To investigate antiviral activity (vRNA and CD4) and safety of a compact nucleoside-sparing regimen of indinavir (IDV) 800mg bid, ritonavir (RTV) 100mg bid, and efavirenz (EFV) 6
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2209)
van Leeuwen R, Sow PS, Bissagnene E, Kityo C, Waweru H, Waalberg E, Lange J; PharmAccess International, Amsterdam, The Netherlands
ISSUES: One of the key debates after the previous World AIDS meeting was how to scale-up access to antiretroviral (ARV) therapy in resource poor settings. The WHO estimates that 6 million people are in direct need of ARV treatment but only a fraction has access to it. CARE (Cohort program to evaluate Access to anti-Ret
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2210)
Adomakoh S, Kumar A, St. John A;;; University of the West Indies, School of Clinical Medicine and Research, St. Michael, Barbados
BACKGROUND: Eastern Caribbean governments have identified PMTCT, as the most urgently required HIV prevention intervention. We estimate cost-effectiveness of PMTCT using the PACTG076 protocol in Barbados and use estimates generated toproduce a model to assess the cost effectiveness under varied treatment settings. METH
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2211)
Alaei K, Alaei A, Mansoori D, Tabar, Heravi, Komasi A, Rangbar H;;; HIV/STI/IDU Care Center, Kermanshah, Islamic Republic of Iran
INTRODUCTION: The assessment of The Kind of drug abuse and the pattern of use and history of prison is very important for evaluation of trend of HIV in the future. METHODS: In this study volunteer addicts were evaluated and IDUs were tested for HIV. RESULTS: Of 731 volunteer addicts, 731 were male (97.5%) & 18 fema
Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPp2212)
Trottier S, Omar R, Desormeaux A, Gagnon MT, Vezina F, Guilbert E, Bergeron M;;; Hospital/University, Quebec, Canada
BACKGROUND: We have developed a topical microbicide gel formulation containing sodium lauryl sulfate (SLS), called the Invisible Condom® that can provide both a physical and a chemical barrier to prevent STDs including HIV/AIDS. We showed that SLS is a potent inhibitor of various HIV and
This information is designed to support, not replace, the relationship that exists between you and your doctor.